Remifentanil and Glycemic Response in Cardiac Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions
Heart DiseasesHyperglycemia
Interventions
DRUG

Remifentanil

Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.

DRUG

Fentanyl

Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.

Trial Locations (1)

15213

UPMC Presbyterian Hospital, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mylan Inc.

INDUSTRY

lead

Kathirvel Subramaniam

OTHER